
    
      This is a randomized, multi-center study conducted in the United States. Men and women with
      osteoporosis will be enrolled in a parallel-group, open-label study design to compare the
      effects of PF708 and Forteo after 24 weeks of treatment. Half of the subjects will be
      randomized to receive PF708, and the other half will be randomized to receive Forteo.
    
  